Janux Therapeutics (JANX) Prices 5.32M Share Offering at $63/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall St futures gain as AI, consulting stocks offset bond-market jitters
- Oil prices rise 2% as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
December 4, 2024 11:12 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchase 238,095 shares of common stock at a price of $62.999 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per... More
